Hazel Yang, MD
Endocrinology, Diabetes & Metabolism · Ashland, KYNPI 1831196807
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 490 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 490 payments — averaging $13.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Novo Nordisk$1K
- Lilly USA, LLC$694
- Merck$605
- AstraZeneca$552
- Sanofi-aventis U.S. LLC$404
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,787100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 88 | $1,215 |
| Novo Nordisk | 99 | $1,088 |
| Lilly USA, LLC | 44 | $694 |
| Merck | 57 | $605 |
| AstraZeneca | 39 | $552 |
| Sanofi-aventis U.S. LLC | 28 | $404 |
| Dexcom, Inc. | 28 | $384 |
| Insulet Corporation | 22 | $330 |
| Medtronic(2 entities) | 14 | $266 |
| Amgen | 14 | $222 |
| Abbott | 11 | $183 |
| Mannkind Corporation | 8 | $156 |
| Tandem Diabetes Care, Inc. | 8 | $145 |
| AbbVie | 9 | $136 |
| Radius Health, Inc. | 2 | $100 |
| BETA Bionics, Inc. | 4 | $86 |
| Amarin Pharma, Inc. | 5 | $76 |
| Amneal Pharmaceuticals LLC | 3 | $51 |
| Bayer | 2 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$6,799 in reported general payments places this provider in the 65th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,039 | $1,150,619 |
| JardianceEmpagliflozin | 481 | $514,492 |
| TrulicityDulaglutide | 198 | $241,055 |
| FarxigaDapagliflozin Propanediol | 181 | $159,965 |
| MounjaroTirzepatide | 125 | $149,390 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $128,658 |
| JanuviaSitagliptin Phosphate | 96 | $123,700 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 467 | $114,659 |
| Tresiba Flextouch U-200Insulin Degludec | 78 | $78,109 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 97 | $62,328 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 70 | $61,170 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $58,626 |
| Novolog FlexpenInsulin Aspart | 237 | $51,652 |
| Bydureon BciseExenatide Microspheres | 28 | $47,639 |
| TradjentaLinagliptin | 53 | $46,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Levemir | $1,088 | $1,217,8471,156 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,215 | $560,991534 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $694 | $409,788389 claims |
| MerckJanuvia, Janumet | $605 | $160,696132 claims |
| AstraZenecaFarxiga | $552 | $159,965181 claims |
| AbbVieSynthroid | $136 | $29,773517 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $404 | $21,63558 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $51 | $18,9021,996 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Ashland
- Moussa AlhajAshland$111K
- George BorstAshland$8K
- Roberto Mitsui AkagiAshland$3K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Mehdi PoorkayLouisville$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.